Answers are grounded in this paper and cite their sources.
SUMMARY Off‐label administration of recombinant activated factor VII (rFVIIa) has extended to multiple patient populations with bleeding complications uncontrolled by conventional measures. Published reports of rFVIIa use through March 2005 for indications not otherwise addressed in this issue were identified from an Internet search and summarized by organ systems. Reported experience is weighed according to published evidence‐based medicine guidelines. Recommendations for use and further studies of rFVIIa are summarized.
No takes yet. Share an insight, caveat, or question.
Steiner et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: